scispace - formally typeset
P

Per Venge

Researcher at Uppsala University

Publications -  457
Citations -  34544

Per Venge is an academic researcher from Uppsala University. The author has contributed to research in topics: Eosinophil cationic protein & Eosinophil. The author has an hindex of 86, co-authored 454 publications receiving 33109 citations. Previous affiliations of Per Venge include University of Helsinki & Karolinska Institutet.

Papers
More filters
Journal Article

Distinctive cationic proteins of the human eosinophil granule: major basic protein, eosinophil cationic protein, and eosinophil-derived neurotoxin.

TL;DR: Observations demonstrate that MBP, ECP, and EDN are distinctive cationic proteins of the human eosinophil granule and that eosInophilgranules from patients with eOSinophilia contain considerably greater quantities of MBP than ECP.
Journal ArticleDOI

Airway Inflammation in Smokers with Nonobstructive and Obstructive Chronic Bronchitis

TL;DR: The findings suggest that the manifestations of inflammation present in the airways of smokers with CB are different in those who have developed obstruction compared with those who has not.
Journal Article

Cationic proteins of human granulocytes. VI. Effects on the complement system and mediation of chemotactic activity.

Per Venge, +1 more
TL;DR: It is suggested that the chymotrypsin-like cationic proteins of human granulocytes after extrusion from the phagocytic cell play an important role for generation of inflammatory mediators.
Journal ArticleDOI

The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein X

TL;DR: It is reported here that two eosinophil-derived proteins, ECP and EPX, may induce the Gordon phenomenon after intraventricular injection and the potency of ECP is far greater than that of EPX and the latter is possibly identical to EDN.
Journal ArticleDOI

Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia.

TL;DR: The data indicate that the novel hypersensitive cardiac troponin I (cTnI) prototype assay may be a powerful aid in the diagnosis and outcome prediction of patients with suspected myocardial ischemia and question any definition of my cardiac infarction.